Curation
PascalFrancis
Racine
Curation
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Renaissance of amantadine in the treatment of Parkinson's disease

Identifieur interne : 000273 ( PascalFrancis/Curation ); précédent : 000272; suivant : 000274

Renaissance of amantadine in the treatment of Parkinson's disease

Auteurs : Pierre J. Blanchet [États-Unis, Canada] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis]

Source :

RBID : Pascal:03-0414877

Descripteurs français

English descriptors

pA  
A01 01  1    @0 0091-3952
A02 01      @0 ADNRA3
A03   1    @0 Adv. neurol.
A05       @2 91
A08 01  1  ENG  @1 Renaissance of amantadine in the treatment of Parkinson's disease
A09 01  1  ENG  @1 Parkinson's Disease
A11 01  1    @1 BLANCHET (Pierre J.)
A11 02  1    @1 VERHAGEN METMAN (Leo)
A11 03  1    @1 CHASE (Thomas N.)
A12 01  1    @1 GORDIN (Ariel) @9 ed.
A12 02  1    @1 KAAKKOLA (Seppo) @9 ed.
A12 03  1    @1 TERÄVÄINEN (Heikki) @9 ed.
A14 01      @1 Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health @2 Bethesda, Maryland @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut.
A14 02      @1 Faculty of Dentistry, University of Montreal @2 Montreal, Quebec @3 CAN @Z 1 aut.
A14 03      @1 Department of Neurology, Rush-Presbytarian-St. Luke ' s Medical Center @2 Chicago, Illinois @3 USA @Z 2 aut.
A15 01      @1 Research Centre, Orion Pharma, Orionintie 1 @2 02100 Espoo @3 FIN @Z 1 aut.
A15 02      @1 Department of Neurology, University of Helsinki @2 Helsinki @3 FIN @Z 2 aut. @Z 3 aut.
A20       @1 251-257
A21       @1 2003
A23 01      @0 ENG
A43 01      @1 INIST @2 15741 @5 354000118596840250
A44       @0 0000 @1 © 2003 INIST-CNRS. All rights reserved.
A45       @0 44 ref.
A47 01  1    @0 03-0414877
A60       @1 P
A61       @0 A
A64 01  1    @0 Advances in neurology
A66 01      @0 USA
C02 01  X    @0 002B17G
C02 02  X    @0 002B02B06
C03 01  X  FRE  @0 Amantadine @2 NK @2 FR @5 02
C03 01  X  ENG  @0 Amantadine @2 NK @2 FR @5 02
C03 01  X  SPA  @0 Amantadina @2 NK @2 FR @5 02
C03 02  X  FRE  @0 Parkinson maladie @5 04
C03 02  X  ENG  @0 Parkinson disease @5 04
C03 02  X  SPA  @0 Parkinson enfermedad @5 04
C03 03  X  FRE  @0 Traitement @5 17
C03 03  X  ENG  @0 Treatment @5 17
C03 03  X  SPA  @0 Tratamiento @5 17
C03 04  X  FRE  @0 Chimiothérapie @5 18
C03 04  X  ENG  @0 Chemotherapy @5 18
C03 04  X  SPA  @0 Quimioterapia @5 18
C03 05  X  FRE  @0 Antiparkinsonien @5 19
C03 05  X  ENG  @0 Antiparkinson agent @5 19
C03 05  X  SPA  @0 Antiparkinsoniano @5 19
C03 06  X  FRE  @0 Homme @5 20
C03 06  X  ENG  @0 Human @5 20
C03 06  X  SPA  @0 Hombre @5 20
C03 07  X  FRE  @0 Agoniste @5 25
C03 07  X  ENG  @0 Agonist @5 25
C03 07  X  SPA  @0 Agonista @5 25
C03 08  X  FRE  @0 Antagoniste @5 26
C03 08  X  ENG  @0 Antagonist @5 26
C03 08  X  SPA  @0 Antagonista @5 26
C03 09  X  FRE  @0 Récepteur dopaminergique @5 27
C03 09  X  ENG  @0 Dopamine receptor @5 27
C03 09  X  SPA  @0 Receptor dopaminérgico @5 27
C03 10  X  FRE  @0 Récepteur glutamate @5 28
C03 10  X  ENG  @0 Glutamate receptor @5 28
C03 10  X  SPA  @0 Receptor glutámato @5 28
C03 11  X  FRE  @0 Récepteur NMDA @5 29
C03 11  X  ENG  @0 NMDA receptor @5 29
C03 11  X  SPA  @0 Receptor NMDA @5 29
C03 12  X  FRE  @0 Stimulant dopaminergique @5 30
C03 12  X  ENG  @0 Dopamine agonist @5 30
C03 12  X  SPA  @0 Estimulante dopaminérgico @5 30
C07 01  X  FRE  @0 Encéphale pathologie @5 37
C07 01  X  ENG  @0 Cerebral disorder @5 37
C07 01  X  SPA  @0 Encéfalo patología @5 37
C07 02  X  FRE  @0 Extrapyramidal syndrome @5 38
C07 02  X  ENG  @0 Extrapyramidal syndrome @5 38
C07 02  X  SPA  @0 Extrapiramidal síndrome @5 38
C07 03  X  FRE  @0 Maladie dégénérative @5 39
C07 03  X  ENG  @0 Degenerative disease @5 39
C07 03  X  SPA  @0 Enfermedad degenerativa @5 39
C07 04  X  FRE  @0 Système nerveux central pathologie @5 40
C07 04  X  ENG  @0 Central nervous system disease @5 40
C07 04  X  SPA  @0 Sistema nervosio central patología @5 40
C07 05  X  FRE  @0 Système nerveux pathologie @5 41
C07 05  X  ENG  @0 Nervous system diseases @5 41
C07 05  X  SPA  @0 Sistema nervioso patología @5 41
N21       @1 286
N82       @1 PSI

Links toward previous steps (curation, corpus...)

Links to Exploration step

Pascal:03-0414877

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Renaissance of amantadine in the treatment of Parkinson's disease</title>
<author>
<name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Faculty of Dentistry, University of Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author>
<name sortKey="Verhagen Metman, Leo" sort="Verhagen Metman, Leo" uniqKey="Verhagen Metman L" first="Leo" last="Verhagen Metman">Leo Verhagen Metman</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Neurology, Rush-Presbytarian-St. Luke ' s Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">03-0414877</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0414877 INIST</idno>
<idno type="RBID">Pascal:03-0414877</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A50</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000273</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Renaissance of amantadine in the treatment of Parkinson's disease</title>
<author>
<name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Faculty of Dentistry, University of Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author>
<name sortKey="Verhagen Metman, Leo" sort="Verhagen Metman, Leo" uniqKey="Verhagen Metman L" first="Leo" last="Verhagen Metman">Leo Verhagen Metman</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Neurology, Rush-Presbytarian-St. Luke ' s Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Advances in neurology</title>
<title level="j" type="abbreviated">Adv. neurol.</title>
<idno type="ISSN">0091-3952</idno>
<imprint>
<date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Advances in neurology</title>
<title level="j" type="abbreviated">Adv. neurol.</title>
<idno type="ISSN">0091-3952</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Agonist</term>
<term>Amantadine</term>
<term>Antagonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Glutamate receptor</term>
<term>Human</term>
<term>NMDA receptor</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Amantadine</term>
<term>Parkinson maladie</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Homme</term>
<term>Agoniste</term>
<term>Antagoniste</term>
<term>Récepteur dopaminergique</term>
<term>Récepteur glutamate</term>
<term>Récepteur NMDA</term>
<term>Stimulant dopaminergique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0091-3952</s0>
</fA01>
<fA02 i1="01">
<s0>ADNRA3</s0>
</fA02>
<fA03 i2="1">
<s0>Adv. neurol.</s0>
</fA03>
<fA05>
<s2>91</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG">
<s1>Renaissance of amantadine in the treatment of Parkinson's disease</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG">
<s1>Parkinson's Disease</s1>
</fA09>
<fA11 i1="01" i2="1">
<s1>BLANCHET (Pierre J.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>VERHAGEN METMAN (Leo)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>CHASE (Thomas N.)</s1>
</fA11>
<fA12 i1="01" i2="1">
<s1>GORDIN (Ariel)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1">
<s1>KAAKKOLA (Seppo)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="03" i2="1">
<s1>TERÄVÄINEN (Heikki)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01">
<s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Faculty of Dentistry, University of Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Department of Neurology, Rush-Presbytarian-St. Luke ' s Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA15 i1="01">
<s1>Research Centre, Orion Pharma, Orionintie 1</s1>
<s2>02100 Espoo</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02">
<s1>Department of Neurology, University of Helsinki</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA15>
<fA20>
<s1>251-257</s1>
</fA20>
<fA21>
<s1>2003</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>15741</s2>
<s5>354000118596840250</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>44 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>03-0414877</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Advances in neurology</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X">
<s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Amantadina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Chimiothérapie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Chemotherapy</s0>
<s5>18</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Quimioterapia</s0>
<s5>18</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Antiparkinsonien</s0>
<s5>19</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Antiparkinson agent</s0>
<s5>19</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Antiparkinsoniano</s0>
<s5>19</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Agoniste</s0>
<s5>25</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Agonist</s0>
<s5>25</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Agonista</s0>
<s5>25</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Antagoniste</s0>
<s5>26</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Antagonist</s0>
<s5>26</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Antagonista</s0>
<s5>26</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Récepteur dopaminergique</s0>
<s5>27</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Dopamine receptor</s0>
<s5>27</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Receptor dopaminérgico</s0>
<s5>27</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Récepteur glutamate</s0>
<s5>28</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Glutamate receptor</s0>
<s5>28</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Receptor glutámato</s0>
<s5>28</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Récepteur NMDA</s0>
<s5>29</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>NMDA receptor</s0>
<s5>29</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Receptor NMDA</s0>
<s5>29</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Stimulant dopaminergique</s0>
<s5>30</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Dopamine agonist</s0>
<s5>30</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Estimulante dopaminérgico</s0>
<s5>30</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>41</s5>
</fC07>
<fN21>
<s1>286</s1>
</fN21>
<fN82>
<s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000273 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000273 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:03-0414877
   |texte=   Renaissance of amantadine in the treatment of Parkinson's disease
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022